PMC8315135_01
(A) alpha fetoprotein (AFP) levels of this patient during the treatment of tomotherapy combined with Neoantigen Reactive T Cells. (B) The lymphocyte levels of this patient during the treatment of tomotherapy combined with Neoantigen Reactive T Cells.
fimmu-12-685126-g001.jpg
PMC8315135_01_fimmu-12-685126-g001.jpg
f1
AFP were listed in  Figure 1A . At the same time, the lymph number gradually increased, and the changes in lymphocytes after per cycle of NRT treatment were shown in  Figure 1B . After four cycle of NRT, the overall efficacy evaluation was SD, and only regular examination was continued.
Plain and enhanced MRI of lesions in different parts of patient in different periods. a-f: right anterior lobe of the liver; g-l: porta hepatis; m-o: left outer lobe of the liver. Efficacy evaluation: PD, Disease progression; SD, Stable disease; PR, Partial response; CR, Complete response.
fimmu-12-685126-g002.jpg
PMC8315135_01_fimmu-12-685126-g002.jpg
f2
The patient's imaging changes were shown in  Figure 2 .
The patient received different treatments at different times. Firstly, tomotherapy combined with Neoantigen Reactive T Cells based immunotherapy(2017-02 to 2017-08, SD). Secondly, PD-1 antibody combined with apatinib(2018-05 to 2018-07, PR). Finally, PD-1 antibody single-drug maintenance treatment (2018-07 until 2020-06, PR in porta hepatis and CR in left outer lobe).
fimmu-12-685126-g003.jpg
PMC8315135_01_fimmu-12-685126-g003.jpg
f3
The target lesion changes at different time points during and after the treatment were listed in  Table 2 .In order to intuitively reflect the patient's prognosis and clinical curative effect, we listed the entire treatment process in  Figure 3 .